Background: Limited data are available on the effect of anemia on mortality in patients with acute myocardial infarction (MI).

Methods: We examined the association of anemia with mortality at 1 year among 30,341 patients hospitalized with acute MI in 1986 (prethrombolytic era, n = 15,584) and 1996 (thrombolytic era, n = 14,757). The records were obtained from the Myocardial Infarction Data Acquisition System, a database of all patients with MI admitted to nonfederal hospitals in New Jersey.

Results: Anemia was present in 996 patients (6.4%) in 1986 and 1510 patients (10.2%, P <.0001) in 1996. In both years, patients with anemia were older, more frequently female and nonwhite, and more likely to have left ventricular dysfunction, non-Q MI and coronary artery bypass graft. In addition, in 1996, patients with anemia were more likely to undergo percutaneous transluminal coronary angioplasty and less likely to have a history of MI. One-year mortality was lower overall in 1996 compared with 1986 (1996 23.6%, 95% CI 22.9-24.3 vs 1986 24.9%, 95% CI 24.2-25.6, P =.0001). In both years, patients with anemia had significantly higher unadjusted risk for 1-year mortality (RR = 1.40, P =.0001 in both years). However, after controlling for demographics, left ventricular dysfunction, arrhythmias, Q versus non-Q MI, comorbid conditions, and revascularization procedures in a multivariable regression model, 1-year mortality in the anemia group was similar to the nonanemia group in both years.

Conclusion: In the Myocardial Infarction Data Acquisition System database, anemia appears to have no significant direct effect on 1-year mortality. The higher unadjusted mortality observed among patients with acute MI and anemia is probably the result of older age, higher comorbidity, and more left ventricular dysfunction.

Download full-text PDF

Source
http://dx.doi.org/10.1067/mhj.2002.124351DOI Listing

Publication Analysis

Top Keywords

myocardial infarction
12
mortality patients
8
patients acute
8
acute myocardial
8
anemia mortality
8
patients
6
anemia
4
anemia 1-year
4
1-year mortality
4
infarction background
4

Similar Publications

Introduction: Medication regimen complexity may be an important risk factor for adverse outcomes in older adults with heart failure. However, increasing complexity is often necessary when prescribing guideline-directed medical therapy at the time of a heart failure hospitalization. We sought to determine whether increased medication regimen complexity following a heart failure hospitalization was associated with worse post-hospitalization outcomes.

View Article and Find Full Text PDF

Empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, has garnered significant interest due to its potential cardiovascular benefits, particularly in patients experiencing acute myocardial infarction (AMI) who are undergoing primary percutaneous coronary intervention (PCI). This systematic review aims to evaluate the effectiveness of Empagliflozin in improving clinical outcomes in this patient population. A systematic review of randomized controlled trials (RCTs) was conducted to assess the effects of Empagliflozin on clinical outcomes in patients with AMI undergoing primary PCI.

View Article and Find Full Text PDF

SUZ12-Increased NRF2 Alleviates Cardiac Ischemia/Reperfusion Injury by Regulating Apoptosis, Inflammation, and Ferroptosis.

Cardiovasc Toxicol

December 2024

Department of Cardiovascular Center, Beijing Tongren Hospital, Capital Medical University, No. 3 Chongwenmennei Street, Dongcheng District, Beijing, 100730, China.

Nuclear factor erythroid 2-related factor 2 (NRF2) is a redox-sensitive transcriptional factor that enables cells to resist oxidant responses, ferroptosis and inflammation. Here, we set out to probe the effects of NRF2 on cardiomyocyte injury under acute myocardial infarction (AMI) condition and its potential mechanism. Human cardiomyocytes were exposed to hypoxia/reoxygenation (H/R) to induce cell injury.

View Article and Find Full Text PDF

Purpose: This meta-analysis aimed to conduct a systematic evaluation of the comparative efficacy and safety of new oral anticoagulants (NOACs) versus warfarin for the treatment of deep venous thrombosis (DVT).

Methods: A systematic computerized search of databases including PubMed, Medline, Web of Science, Embase, Cochrane Library, and www.

Clinicaltrials: gov .

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!